[The immunomodulating action of extracorporeal treatment methods and the late effect from their use in patients with rheumatoid arthritis].

Unlike hemocarboperfusion (HCP), plasmapheresis (PA) produces a long-term effect in the treatment of serious cases of rheumatoid arthritis. This explains why the rebound syndrome occurs in PA two times less frequently. The analysis of the immunomodifying action of both the treatments and comparison of their efficacy suggest the conclusion that long-term and complete remissions are associated with the immunosuppressive effects, while the development of exacerbations accompanies the immunomodifying effect.

[The prediction of the late effect of charcoal hemoperfusion in rheumatoid arthritis patients].

Hemocarboperfusion is effectively used for the treatment of serious cases of rheumatoid arthritis (RA). The effectiveness of the treatment may be decreased by possible development of the rebound syndrome (RS) after the treatment. The useful retrospective frequency analysis does not often allow predicting the development of RS.